DAFTAR PUSTAKA

Aaltonen KE, Rosendahl AH, Olsson H, Malmström P, Hartman L, Fernö M, 2014. Association Between Insulin-like Growth Factor-1 Receptor (IGF-1R) Negativity and Poor Prognosis in a Cohort of Women with Primary Breast Cancer. *BMC Cancer*, Vol. 14, No. 794, pp. 1-13.

Aini N, Kasno, Basuki R, 2015. Hubungan Antara Ekspresi Protein Her-2/Neu dengan Derajat Diferensiasi Penderita Karsinoma Payudara Jenis Duktus Invasif. *Jurnal Kedokteran Muhammadiyah*, Vol. 2, No. 1, pp 12-5.

Al-Janabi S, van Slooten HJ, Visser M, van der Ploeg T, van Diest PJ, Jiwa M, 2013. Evaluation of Mitotic Activity Index in Breast Cancer Using Whole Slide Digital Images. *PLoS ONE*, Vol. 8, No. 12, pp. 1-9.

Allemani C, Weir HK, Carreira H *et al.*, 2015. Global Surveillance of Cancer Survival 1995–2009: Analysis of Individual Data for 25.676.887 Patients from 279 Population-Based Registries in 67 Countries (CONCORD-2). *Lancet*, Vol. 385, No. 9972, pp. 1-34.

Allison KH, 2012. Molecular Pathology of Breast Cancer. What A Pathologist Needs to Know. *Am J Clin Pathol*, Vol. 138, No. 6, pp. 770-80.

Allred C, Miller K, Viale G, Brogi E, Isola J, 2012. Molecular Testing for Estrogen Receptor, Progesterone Receptor and HER2. In (Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ, eds) *WHO Classification of Tumours of The Breast*, 4th ed. Lyon: International Agency for Research on Cancer, pp. 22-3.

American Cancer Society, 2015. *Cancer Facts and Figures 2015*. Atlanta: American Cancer Society Inc, pp. 9-11.

American Cancer Society, 2017. *Breast Cancer Facts & Figures 2017-2018*. Atlanta: American Cancer Society, Inc, pp. 1-44.

Angahar LT, 2017. An Overview of Breast Cancer Epidemiology, Risk Factors, Pathophysiology and Cancer Risks Reduction. *MedCrave Online Journal of Biology and Medicine*, Vol. 1, No. 4, pp. 1-5.

Aryandono T, Harijadi, Soeripto, 2006. Hormone Receptor Status of Operable Breast Cancers in Indonesia: Correlation with Other Prognostic Factors and Survival. *Asian Pacific Journal of Cancer Prevention*, Vol. 7, pp. 321-4.

Baak JPA, Gudlaugsson E, Skaland I *et al.*, 2009. Proliferation is The Strongest Prognosticator in Node-Negative Breast Cancer: Significance, Error

Sources, Alternatives and Comparison with Molecular Prognostic Markers. *Breast Cancer Res Treat*, Vol. 115, No.2, pp. 241-54.

Badan Registrasi Kanker Perhimpunan Dokter Spesialis Patologi Indonesia, 2017. *Kanker di Indonesia Tahun 2013: Data Histopatologik*. Jakarta: Yayasan Kanker Indonesia.

Baker AT, Zlobin A, Osipo C, 2014. Notch-EGFR/HER2 Bidirectional Crosstalk in Breast Cancer. *Front Oncol*, Vol. 4, No. 360, pp. 1-15.

Bavle RM, 2014. Enigmatic Morpho Insight: Mitosis at a Glance. *J Oral Maxillofac Pathol*, Vol. 18, pp. 2-5.

Bonert M, Tate AJ, 2017. Mitotic Counts in Breast Cancer Should be Standardized with a Uniform Sample Area. *BioMed Eng OnLine*, Vol 16, No. 1, pp. 1-8.

Boone DN, Lee AV, 2012. Targeting the Insulin-like Growth Factor Receptor: Developing Biomarkers from Gene Expression Profiling. *Crit Rev Oncog*, Vol. 17, No. 2, pp. 161-73.

Browne BC, Eustace AJ, Kennedy S *et al*., 2012. Evaluation of IGF-1R and Phosphorylated IGF-1R as Targets in HER2-positive Breast Cancer Cell Lines and Tumours. *Breast Cancer Res Treat*, Vol. 136, No. 1, pp. 717-27.

Bueno-de-Mesquita JM, Nuyten DSA, Wesseling J, van Tinteren H, Linn SC, van de Vijver MJ, 2010. The Impact of Inter-observer Variation in Pathological Assessment of Node-negative Breast Cancer on Clinical Risk Assessment and Patient Selection for Adjuvant Systemic Treatment. *Annals of Oncology*, Vol. 21, No. 1, pp. 40-7.

Chen HX, Sharon E, 2013. IGF-1R as An Anti-Cancer Target-Trials and Tribulations. *Chinese Journal of Cancer*, Vol. 32, No. 5, pp. 242-52.

Coates AS, Winer EP, Goldhirsch A *et al.*, 2015. Tailoring Therapies-Improving The Management of Early Breast Cancer: St Gallen International Expert Consensus on The Primary Therapy of Early Breast Cancer 2015. *Annals of Oncology*, Vol. 26, No. 8, pp. 1533-46.

Colditz G, Chia KS, 2012. Epidemiology Invasive Breast Carcinoma. In (Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ, eds) *WHO Classification of Tumours of The Breast*, 4th ed. Lyon: International Agency for Research on Cancer, pp. 14-7.

Curado MP, 2011. Breast Cancer in The World: Incidence and Mortality. *Salud Publica Mex*, Vol. 53, No. 5, pp. 372-84.

Dai X, Xiang L, Li T, Bai Z, 2016. Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes. *Journal of Cancer*, Vol. 7, No. 10, pp. 1281-94.

Denduluri SK, Idowu O, Wang Z *et al.*, 2015. Insulin-like Growth Factor (IGF) Signaling in Tumorigenesis and The Development of Cancer Drug Resistance. *Genes Dis*, Vol. 2, No. 1, pp. 13-25.

De Groot S, Charehbili A, van Laarhoven HWM *et al*., 2016. Insulin-like Growth Factor-1 Receptor Expression and IGF1R 3129G >T Polymorphism are Associated with Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: Results from The NEOZOTAC Trial (BOOG 2010-01). *Breast Cancer Research*, Vol. 18, No. 3, pp. 1-11.

De Ruijter, Veeck J, de Hoon JPJ, van Engeland M, Tjan-Heijnen VC, 2011. Characteristics of Triple-negative Breast Cancer. *J Cancer Res Clin Oncol*, Vol. 137, No. 1, pp. 183-92.

Devi CRB, Tang TS, Corbex M, 2012. Incidence and Risk Factors for Breast Cancer Subtypes in Three Distinct South-East Asian Ethnic Groups: Chinese, Malay and Natives of Sarawak, Malaysia. *Int J Cancer*, Vol. 131, No. 12, pp. 2869-77.

Dey N, Leyland-Jones B, De P, 2016. HER2 Signaling Network in Advanced Breast Cancer: Opportunities for Combination Therapies. In (Dey N, De P, Leyland-Jones B, eds) *PI3K-mTOR in Cancer and Cancer Therapy*. New York: Springer Science+Business Media, pp. 231-61.

Dittrich A, Gautrey H, Browell D, Tyson-Capper A, 2014. The HER2 Signaling Network in Breast Cancer-Like A Spider in its Web. *J Mammary Gland Biol Neoplasia*, Vol. 19, No. 3-4, pp. 253-70. DOI 10.1007/s10911-014-9329-5.

Duru N, Candas D, Jiang G, Li JJ, 2014. Breast Cancer Adaptive Resistance: HER2 and Cancer Stem Cell Repopulation in A Heterogeneous Tumor Society. *J Cancer Res Clin Oncol*, Vol. 140, pp. 1-14.

Ekyalongo RC, Yee D, 2017. Revisiting The IGF-1R as A Breast Cancer Target. *Npj Precision Oncology*, Vol. 1, No. 14, pp. 1-7.

Ellis IO, Collins L, Ichihara S, MacGrogan G, 2012. Invasive Carcinoma of No Special Type. In (Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ, eds) *WHO Classification of Tumours of The Breast*, 4th ed. Lyon: International Agency for Research on Cancer, pp. 34-8.

Ellis IO, Simpson JS, Reis-Filho JS, Decker T, 2012. Grading Invasive Breast Carcinoma. In (Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver

MJ, eds) *WHO Classification of Tumours of The Breast*, 4th ed. Lyon: International Agency for Research on Cancer, pp. 19-20.

Fan L, Goss PE, Strasser-Weippl K, 2015. Current Status and Future Projections of Breast Cancer in Asia. *Breast Care (Basel)*, Vol. 10, No. 6, pp. 372-8.

Farabaugh SM, Boone DN, Lee AV, 2015. Role of IGF-1R in Breast Cancer Subtypes, Stemness and Lineage Differentiation. *Frontiers in Endocrinology*, Vol. 6, No. 59, pp. 1-12.

Ferlay J, Héry C, Autier P, Sankaranarayanan R, 2010. Global Burden of Breast Cancer. In (Li CI, ed) *Breast Cancer Epidemiology*. New York: Springer Science+Business Media, pp. 1-19.

Ferlay J, Soerjomataram I, Dikshit R *et al*., 2015. Cancer Incidence and Mortality Worldwide: Sources, Methods and Major Patterns in GLOBOCAN 2012. *International Journal of Cancer*, Vol. 136, No. 5, pp. 359-86.

Fink MY, Chipuk JE, 2013. Survival of HER2-Positive Breast Cancer Cells: Receptor Signaling to Apoptotic Control Centers. *Genes & Cancer*, Vol. 4, No. 5-6, pp.187-95.

Fu P, Ibusuki M, Yamamoto Y *et al*., 2011. Insulin-like Growth Factor-1 Receptor Gene Expression is Associated with Survival in Breast Cancer: A Comprehensive Analysis of Gene Copy Number, mRNA and Protein Expression. *Breast Cancer Res Treat*, Vol. 130, No. 1, pp. 307-17.

Gajria D, Chandarlapaty S, 2011. HER2-amplified Breast Cancer: Mechanisms of Trastuzumab Resistance and Novel Targeted Therapies. *Expert Rev Anticancer Ther*. Vol. 11, No. 2, pp. 263-75.

Ghoncheh M, Pournamdar Z, Salehiniya H, 2016. Incidence and Mortality and Epidemiology of Breast Cancer in The World. *Asian Pac J Cancer Prev*, *Cancer Control in Western Asia Special Issue*, Vol. 17, pp. 43-6.

Gnant M, Harbeck N, Thomssen C, 2017. St. Gallen/Vienna 2017: A Brief Summary of The Consensus Discussion About Escalation and De-Escalation of Primary Breast Cancer Treatment. *Breast Care*, Vol. 12, No. 2, pp. 102-7.

Goldhirsch A, Winer EP, Coates AS *et al*., 2013. Personalizing The Treatment of Women with Early Breast Cancer: Highlights of The St Gallen International Expert Consensus on The Primary Therapy of Early Breast Cancer 2013. *Annals of Oncology*, Vol. 24, pp. 2206-23.

Gradishar WJ, Anderson BO, Balassanian R *et al*., 2017. NCCN Guidelines® Insights Breast Cancer, Version 1.2017. *J Natl Compr Canc Netw*, Vol. 15, No. 4, pp. 433-51.

Gruver AM, Portier BP, Tubbs RR, 2011. Molecular Pathology of Breast Cancer. The Journey from Traditional Practice Toward Embracing The Complexity of A Molecular Classification. *Arch Pathol Lab Med*, Vol. 135, pp. 544-57.

Hammond MEH, Hayes DF, Dowsett M *et al.*, 2010. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. *Archives of Pathology and Laboratory Medicine,* Vol. 134, No. 6, pp. 907-22.

Harahap WA, 2014. Metilasi Promoter Breast Cancer Gene-1 dan Hubungannya dengan Faktor Prognostik Karsinoma Payudara Sporadik Premenopause pada Etnis Minang. *Disertasi*, Universitas Andalas, Indonesia.

Hein SM, Haricharan S, Johnston AN *et al.*, 2016. Luminal Epithelial Cells within The Mammary Gland can Produce Basal Cells upon Oncogenic Stress. *Oncogene,* Vol. 35, No. 11, pp. 1461-7.

Hoda SA, 2014. Invasive Ductal Carcinoma: Assessment of Prognosis with Morphologic and Biologic Markers. In (Hoda SA, Brogi E, Koerner FC, Rosen PP, eds) *Rosen's Breast Pathology*, 4th ed. Philadelphia: Wolters Kluwer, pp. 413-67.

Hoda SA, 2014. Precarcinomatous Breast Disease: Epidemiologic, Pathologic and Clinical Considerations. In (Hoda SA, Brogi E, Koerner FC, Rosen PP, eds) *Rosen's Breast Pathology*, 4th ed. Philadelphia: Wolters Kluwer, pp. 309-30.

Hoda SA, Resetkova E, 2014. Pathologic Examination of Breast and Lymph Node Specimens, Including Sentinel Lymph Nodes. In (Hoda SA, Brogi E, Koerner FC, Rosen PP, eds) *Rosen's Breast Pathology*, 4th ed. Philadelphia: Wolters Kluwer, pp. 1263-5.

Humphries MP, Jordan VC, Speirs V, 2015. Obesity and Male Breast Cancer: Provocative Parallels?. *BMC Medicine,* Vol. 13, No. 134, pp. 1-9.

Hutagalung SB, Mulyadi IK, Artha IGA, 2014. Ekspresi Ki-67 dan HER-2/neu Berhubungan dengan Derajat Histopatologik Karsinoma Payudara Invasif *No Special Type* (NST). *Majalah Patologi Indonesia*, Vol. 23, No. 2, pp. 45-50.

Iams WT, Lovly CM, 2015. Molecular Pathways: Clinical Applications and Future Direction of Insulin-Like Growth Factor-1 Receptor Pathway Blockade. *Clin Cancer Res*, Vol. 21, No. 19, pp. 4270-77.

Ignatov T, Eggemann H, Burger E, Fettke F, Costa SD, Ignatov A, 2015. Moderate Level of HER2 Expression and Its Prognostic Significance in

Breast Cancer with Intermediate Grade. *Breast Cancer Res Treat*, Vol. 151, No. 1, pp. 357-64.

Iqbal N, Iqbal N, 2014. Human Epidermal Growth Factor Receptor-2 (HER-2) in Cancers: Overexpression and Therapeutic Implications. *Molecular Biology International*. Hindawi Publishing Corporation, 852748, pp. 1-9. http://dx.doi.org/10.1155/2014/852748, diakses pada tanggal 20 Oktober 2017.

Janssen JA, Varewijck AJ, 2014. IGF-IR Targeted Therapy: Past, Present and Future. *Frontiers in Endocrinology*, Vol. 5, No. 224, pp. 1-7.

Jatiluhur IM, Yantisetiasti A, Hassan AH, Hernowo BS, 2014. Hubungan antara HER-2/neu dan Ki-67 dengan Respon Kemoterapi Neoadjuvan pada Karsinoma Payudara Lanjut Lokal. *Majalah Patologi Indonesia*, Vol. 23, No. 3, pp. 32-40.

Kadi TA, Hoesin F, 2014. Ekspresi *Matrix Metalloproteinase-9* (MMP-9), HER-2/neu dan Metastasis Kelenjar Getah Bening pada Karsinoma Payudara Duktal Invasif. *Majalah Patologi Indonesia*, Vol. 23, No. 1, pp. 28-34.

Kamarlis RK, 2017. Analisa Korelasi *SOX2* dan *p63* dalam Penentuan Gambaran Histopatologik Kanker Payudara Jenis *Basal-like* dan *Non Basal-like*. *Disertasi*, Universitas Sumatera Utara, Indonesia.

Karlsson E, 2014. Prognosis and Predictive Factors in Human Breast Cancer During Tumor Progression. *Thesis*, Karolinska Institutet, Swedia.

Kasprzak A, Kwasniewski W, Adamek A, Gozdzicka-Jozefiak A, 2017. Insulin-like Growth Factor (IGF) Axis in Cancerogenesis. *Mutat Res Rev Mutat Res*, Vol. 772, pp. 78-104.

Kementerian Kesehatan RI, 2016. Kanker Payudara. Pusat Data dan Informasi Kementerian Kesehatan RI (Info Datin), pp. 1-11. Available from: http://www.depkes.go.id/folder/view/01/structure-publikasi-pusdatin-info-datin.html, diakses pada tanggal 29 Mei 2018.

Khambri D, 2015. Hubungan Ekspresi *Androgen Receptor* dengan Faktor Prognostik Karsinoma Payudara di Sumatera Barat. *Disertasi*, Universitas Andalas, Indonesia.

Kosasih J, Artha IGA, 2011. Hubungan Overekspresi Topoisomerase II Alfa dengan Overekspresi Her-2/neu dan Berbagai Derajat Histologik Karsinoma Duktal Invasif Tidak Spesifik Payudara. *Majalah Patologi Indonesia*, Vol. 20, No. 1, pp. 6-13.

Köstler WJ, Hudelist G, Rabitsch W *et al*., 2006. Insulin-like Growth Factor-1 Receptor (IGF-1R) Expression Does Not Predict for Resistance to

Trastuzumab-based Treatment in Patients with HER-2/neu Overexpressing Metastatic Breast Cancer. *J Cancer Res Clin Oncol*, Vol. 132, No. 1, pp. 9-18.

Kumar V, Abbas AK, Aster JC, 2015. Neoplasia. In (Kumar V, Abbas AK, Aster JC, eds) *Robbins and Cotran Pathologic Basis of Disease*, 9th ed. Philadelphia: Elsevier Saunders, pp. 321-4.

Lee LH, Yang H, Bigras G, 2014. Current Breast Cancer Proliferative Markers Correlate Variably Based on Decoupled Duration of Cell Cycle Phases. *Scientific Reports*, Vol. 4, No. 5122, pp. 1-8.

Lester SC, 2015. The Breast. In (Kumar V, Abbas AK, Aster JC, eds) *Robbins and Cotran Pathologic Basis of Disease*, 9th ed. Philadelphia: Elsevier Saunders, pp. 1051-64.

Lin F, Shi J, 2015. Standardization of Diagnostic Immunohistochemistry. In (Lin F, Prichard J, eds) *Handbook of Practical Immunohistochemistry, Frequently Asked Questions*, 2nd ed. New York: Springer Science+Business Media, pp. 17-30.

Li X, Oprea-Ilies GM, Krishnamurti U, 2017. New Developments in Breast Cancer and Their Impact on Daily Practice in Pathology. *Archives of Pathology and Laboratory Medicine*, Vol. 141, No. 4, pp. 490-8.

Ly A, Lester SC, Dillon D, 2012. Prognostic Factors for Patients with Breast Cancer: Traditional and New. *Surgical Pathology*, Vol. 5, pp. 775-85.

Makki J, 2015. Diversity of Breast Carcinoma: Histological Subtypes and Clinical Relevance. *Clinical Medicine Insights: Pathology*, Vol. 8, pp. 23-31.

Martin HL, Smith L, Tomlinson DC, 2014. Multidrug-resistant Breast Cancer: Current Perspectives. *Breast Cancer: Targets and Therapy*, Vol. 6, pp. 1-13.

Masoud V, Pagès G, 2017. Targeted Therapies in Breast Cancer: New Challenges to Fight Against Resistance. *World J Clin Oncol*, Vol. 8, No. 2, pp. 120-34.

Matsumoto A, Jinno H, Ando T *et al*., 2016. Biological Markers of Invasive Breast Cancer. *Japanese Journal of Clinical Oncology*, Vol. 46, No. 2, pp. 99-105.

Meuten DJ, Moore FM, George JW, 2016. Mitotic Count and The Field of View Area: Time to Standardize. *Veterinary Pathology*, Vol. 53, No. 1, pp. 7-9.

Mitchell RN, 2015. The Cell as a Unit of Health and Disease. In (Kumar V, Abbas AK, Aster JC, eds) *Robbins and Cotran Pathologic Basis of Disease*, 9 th ed. Philadelphia: Elsevier Saunders, pp. 1-29.

Mohan H, 2015. *Textbook of Pathology*, 7th ed. New Delhi: Jaypee Brothers Medical Publishers, pp. 745-58.

Moinfar F, 2007. *Essentials of Diagnostic Breast Pathology, A Practical Approach.* New York: Springer-Verlag, pp. 2-5.

Mook S, 2011. Prognostic Factors in Breast Cancer. One Fits All?. *Thesis*, University of Amsterdam, Netherlands.

Morrow M, Rutgers E, 2012. Clinical Features Invasive Breast Carcinoma. In (Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ, eds) *WHO Classification of Tumours of The Breast*, 4th ed. Lyon: International Agency for Research on Cancer, pp. 18-9.

Mousavi SM, Mohaghegghi MA, Mousavi-Jerrahi A, Nahvijou A, Seddighi Z, 2006. Burden of Breast Cancer in Iran: A Study of The Tehran Population Based Cancer Registry. *Asian Pacific Journal of Cancer Prevention*, Vol. 7, pp. 571-4.

Muendlein A, Lang AH, Geller-Rhomberg S *et al*., 2013. Association of A Common Genetic Variant of The IGF-1 Gene with Event-Free Survival in Patients with HER2-Positive Breast Cancer. *J Cancer Res Clin Oncol*, Vol. 139, No. 3, pp. 491-8.

Muhartono, Ramanisa R, Mutiara H, Riduan RJ, 2016. Hubungan antara Status Reseptor Estrogen, Reseptor Progesteron dan Human Epidermal Growth Factor Receptor-2 dengan Derajat Keganasan Karsinoma Payudara Invasif. *Majalah Kedokteran Andalas*, Vol. 39, No. 2, pp. 65-72.

Mulligan AM, O'Malley FP, 2015. The Breast. In (Strayer DS, Rubin E, Saffitz JE, Schiller AL, eds) *Rubin's Pathology Clinicopathologic Foundations of Medicine*, 7th ed. Philadelphia: Wolters Kluwer, pp. 1064-78.

Nelson H, Maulani H, Farida A, Saleh MI, 2014. Hubungan antara Ekspresi *Vascular Endothelial Growth Factor* (VEGF) dengan Karakteristik Klinikopatologik Karsinoma Payudara Duktal Invasif. *Majalah Patologi Indonesia*, Vol. 23, No. 1, pp. 48-53.

Ng CH, Pathy NB, Taib NA *et al.*, 2011. Comparison of Breast Cancer in Indonesia and Malaysia-A Clinicopathological Study Between Dharmais Cancer Centre Jakarta and University Malaya Medical Centre, Kuala Lumpur. *Asian Pacific Journal of Cancer Prevention*, Vol. 12, pp. 2943-6.

Nielsen TO, Andrews HN, Cheang M *et al.*, 2004. Expression of The Insulin-like Growth Factor-1 Receptor and Urokinase Plasminogen Activator in Breast Cancer is Associated with Poor Survival: Potential for Intervention with 17-Allylamino Geldanamycin. *Cancer Res*, Vol. 64, No. 1, pp. 286-91.

Nishimura R, Osako T, Okumura Y, Hayashi M, Toyozumi Y, Arima N, 2010. Ki-67 as A Prognostic Marker According to Breast Cancer Subtype and A Predictor of Recurrence Time in Primary Breast Cancer. *Exp Ther Med*, Vol. 1, No. 5, pp. 747-54.

Norum JH, Andersen K, Sørlie T, 2014. Lessons Learned from The Intrinsic Subtypes of Breast Cancer in The Quest for Precision Therapy. *Br J Surg*, Vol. 101, No. 8, pp. 925-38.

Ossovskaya V, Wang Y, Budoff A *et al.*, 2011. Exploring Molecular Pathways of Triple-Negative Breast Cancer. *Genes & Cancer*, Vol. 2, No. 9, pp. 870-9.

Pareja F, Pines G, Yarden Y, 2015. The EGFR/ERBB Receptor Family. In (Wheeler DL, Yarden Y, eds) *Receptor Tyrosine Kinases: Family and Subfamilies*. Switzerland: Springer International Publishing, pp. 107-64.

Parise CA, Caggiano V, 2014. Breast Cancer Survival Defined by The ER/PR/HER2 Subtypes and A Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers. *Journal of Cancer Epidemiology*, Hindawi Publishing Corporation, Article ID 469251, pp. 1-11.

Payandeh M, Shahriari-Ahmadi A, Sadeghi M, Sadeghi E, 2016. Correlations Between HER-2 Expression and Other Prognostic Factors in Breast Cancer: Inverse Relations with The Ki-67 Index and P53 Status. *Asian Pac J Cancer Prev*, Vol. 17, No. 3, pp. 1015-18.

Perou CM, Sorlie T, Eisen MB *et al.*, 2000. Molecular Portraits of Human Breast Tumours. *Nature*, Vol. 406, No. 6797, pp. 747-52.

Pinder SE, Lee AHS, Ellis IO, 2014. The Breasts. In (Herrington CS, ed) *Muir's Textbook of Pathology*, 15th ed. Boca Raton: Taylor and Francis Group, pp. 451-60.

Prichard J, 2015. Immunohistochemistry Quality Management and Regulation. In (Lin F, Prichard J, eds) *Handbook of Practical Immunohistochemistry, Frequently Asked Questions*, 2nd ed. New York: Springer Science+Business Media, pp. 1-16.

Rahman A, Sampepajung D, Hamdani W, 2014. Correlation Between HER-2/neu and Hormonal Receptor with Histopathology Grading on Young Women

Breast Cancer, pp. 1-12. Available from: http://pasca.unhas.ac.id/jurnal/ diakses pada tanggal 29 Mei 2018.

Reinholz MM, Chen B, Dueck AC, 2017. IGF-1R Protein Expression is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2^{+} Breast Cancer from The North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831. *Clin Cancer Res*, Vol. 23, No. 15, pp. 4203-11.

Rosa M, 2015. Advances in The Molecular Analysis of Breast Cancer: Pathway Toward Personalized Medicine. *Cancer Control*, Vol. 22, No. 2, pp. 211-9.

Roux L, Racoceanu D, Loménie N *et al.*, 2013. Mitosis Detection in Breast Cancer Histological Images An ICPR 2012 Contest. *J Pathol Inform*, Vol. 4, pp.1-7.

Russell CA, 2014. Personalized Medicine for Breast Cancer: It is A New Day!. *The American Journal of Surgery*, Vol. 207, pp. 321-5.

Sakhdari A, Hutchinson L, Cosar EF, 2015. Molecular Pathology of HER Family of Oncogenes in Breast Cancer: HER-2 Evaluation and Role in Targeted Therapy. In (Khan A, Ellis IO, Hanby AM, Cosar EF, Rakha EA, Kandil D, eds) *Precision Molecular Pathology of Breast Cancer*. New York: Springer Science+Business Media, pp. 119-36.

Sanguinetti A, Polistena A, Lucchini R *et al.*, 2016. Male Breast Cancer, Clinical Presentation, Diagnosis and Treatment: Twenty Years of Experience in Our Breast Unit. *International Journal of Surgery Case Reports*, Vol. 20S, pp. 8-11.

Sarfstein R, Werner H, 2015. The INSR/IGF1R Receptor Family. In (Wheeler DL, Yarden Y, eds) *Receptor Tyrosine Kinases: Family and Subfamilies*. Switzerland: Springer International Publishing, pp. 297-320.

Shin SJ, Gong G, Lee HJ *et al.*, 2014. Positive Expression of Insulin-like Growth Factor-1 Receptor is Associated with A Positive Hormone Receptor Status and A Favorable Prognosis in Breast Cancer. *J Breast Cancer*, Vol. 17, No. 2, pp. 113-20.

Shokouh TZ, Ezatollah A, Barrand P, 2015. Interrelationships Between Ki67, HER2/neu, p53, ER and PR Status and Their Associations with Tumor Grade and Lymph Node Involvement in Breast Carcinoma Subtypes. *Medicine*, Vol. 94, No. 32, pp. 1-6.

Siregar KB, 2015. HER-2 Overexpression in Relation to Breast Cancer Histopathological Grading: A Promising Prognostic and Predictive

Biomarker for Breast Cancer. *Journal of Health, Medicine and Nursing*, Vol. 21, pp. 1-3.

Skaland I, van Diest PJ, Janssen EAM, Gudlaugsson E, Baak JPA, 2008. Prognostic Differences of World Health Organization-Assessed Mitotic Activity Index and Mitotic Impression by Quick Scanning in Invasive Ductal Breast Cancer Patients Younger than 55 Years. *Human Pathology*, Vol. 39, No. 4, pp. 584-90.

Soliman NA, Yussif SM, 2016. Ki-67 as A Prognostic Marker According to Breast Cancer Molecular Subtype. *Cancer Biol Med*, Vol. 13, No. 4, pp. 496-504.

Steinbeck RG, 2001. Pathologic Mitoses and Pathology of Mitosis in Tumorigenesis. *Eur J Histochem*, Vol. 45, pp. 311-18.

Strumfa I, Vanags A, Abolins A, Gardovskis J, 2012. Pathology of Breast Cancer: from Classic Concepts to Molecular Pathology and Pathogenesis. *Acta Chirurgica Latviensis*, Vol. 12, No. 1, pp. 59-66.

Sun WY, Yun HY, Song YJ *et al*., 2015. Insulin-like Growth Factor-1 Receptor Expression in Breast Cancer Tissue and Mammographic Density. *Mol Clin Oncol*, Vol. 3, No. 3, pp. 572-80.

Tan PH, Sahin AA, 2017. *Atlas of Differential Diagnosis in Breast Pathology, Atlas of Anatomic Pathology*. Springer Science+Business Media, pp. 417-35.

Tinambunan A, Sulastri H, Julianita F, Bahar E, 2013. Hubungan Ekspresi Top2A dengan Karakteristik Histopatologi dan Status Reseptor Hormon pada Karsinoma Payudara Her-2 Positif. *Majalah Patologi Indonesia*, Vol. 22, No. 2, pp. 31-7.

Veta M, van Diest PJ, Jiwa M, Al-Janabi S, Pluim JPW, 2016. Mitosis Counting in Breast Cancer: Object Level Interobserver Agreement and Comparison to An Automatic Method. *PLoS ONE*, Vol. 11, No. 8, pp. 1-13.

Veta M, van Diest PJ, Willems SM *et al.*, 2015. Assessment of Algorithms for Mitosis Detection in Breast Cancer Histopathology Images. *Medical Image Analysis*, Vol. 20, pp. 237-48.

Voudouri K, Berdiaki A, Tzardi M, Tzanakakis GN, Nikitovic D, 2015. Insulin-like Growth Factor and Epidermal Growth Factor Signaling in Breast Cancer Cell Growth: Focus on Endocrine Resistant Disease. *Analytical Cellular Pathology*, Hindawi Publishing Corporation, 975495, pp. 1-10. http://dx.doi.org/10.1155/2015/975495.

Viale G, 2012. The Current State of Breast Cancer Classification: Symposium Article. *Annals of Oncology*, Vol. 23, Supplement 10, pp. x207-10.

Vu T, Claret FX, 2012. Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer. *Frontiers in Oncology*, Vol 2, No. 62, pp.1-6.

Widodo I, Dwianingsih EK, Triningsih E, Utoro T, Soeripto, 2014. Clinicopathological Features of Indonesian Breast Cancers with Different Molecular Subtypes. *Asian Pac J Cancer Prev*, Vol. 15, No. 15, pp. 6109-13.

Wu J, Yu E, 2014. Insulin-like Growth Factor Receptor-1 (IGF-IR) as A Target for Prostate Cancer Therapy. *Cancer Metastasis Rev*, Vol. 33, pp. 607-17.

Wu Y, Sahin AA, 2014. Molecular Classification and Testing of Breast Carcinoma. In (Hoda SA, Brogi E, Koerner FC, Rosen PP, eds) *Rosen's Breast Pathology*, 4th ed. Philadelphia: Wolters Kluwer, pp. 1337-49.

Yan J, Liu XL, Han LZ *et al.*, 2015. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α Expression in Invasive Ductal Breast Cancer Patients and Correlations with Prognosis. *Asian Pac J Cancer Prev*, Vol. 16, No. 2, pp.823-9.

Yan S, Jiao X, Li K, Zou H, 2015. The Impact of IGF-1R Expression on The Outcomes of Patients with Breast Cancer: A Meta-analysis. *Onco Target and Therapy*, Vol. 8, pp. 279-87.

Yerushalmi R, Gelmon KA, Leung S *et al.*, 2012. Insulin-like Growth Factor-1 Receptor (IGF-1R) in Breast Cancer Subtypes. *Breast Cancer Res Treat*, Vol. 132, No. 1, pp. 131-42.

Yip CH, 2009. Breast Cancer in Asia. *Methods in Molecular Biology*, Vol. 471, pp. 51-64.

Yip CH, Taib NAM, Mohamed I, 2006. Epidemiology of Breast Cancer in Malaysia. *Asian Pacific Journal of Cancer Prevention*, Vol. 7, pp. 369-74.

Youlden DR, Cramb SM, Yip CH, Baade PD, 2014. Incidence and Mortality of Female Breast Cancer in The Asia Pacific Region. *Cancer Biology and Medicine*, Vol. 11, No. 2, pp. 101-15.

Yu LY, Tang J, Zhang CM *et al.*, 2017. New Immunotherapy Strategies in Breast Cancer. *International Journal of Environmet Research and Public Health*, Vol. 14, No. 68, pp. 1-18.

Zha J, Lackner MR, 2010. Targeting The Insulin-like Growth Factor-1 Receptor Pathway for Cancer Therapy. *Clin Cancer Res*, Vol. 16, No. 9, pp. 2512-7.

Zhong H, Chekmareva M, Deen M, May M, Deak S, Barnard N, 2014. Benign Reactive Lesion with Atypical Mitosis: New Example of An Old Story. *IJCRI*, Vol. 5, No. 3, pp. 235-39.